Prevalence and Risk Factors of Artificial Urinary Sphincter Revision in Nonneurological Male Patients.


Journal

The Journal of urology
ISSN: 1527-3792
Titre abrégé: J Urol
Pays: United States
ID NLM: 0376374

Informations de publication

Date de publication:
Nov 2021
Historique:
pubmed: 30 6 2021
medline: 28 10 2021
entrez: 29 6 2021
Statut: ppublish

Résumé

The main objective of this study was to assess the prevalence and risk factors of male artificial urinary sphincter (AUS) mechanical failures and nonmechanical failures. The charts of all male patients who underwent AUS implantation between 2004 and 2020 in 16 centers were retrospectively reviewed. Patients with neurogenic stress urinary incontinence (SUI) were excluded as well as revisions/explantations due to infections and/or erosions. The causes of revision were divided into mechanical failures (fluid loss or malfunction from any components of the AUS), nonmechanical failures (urethral atrophy, recurrence/persistence of SUI despite normally functioning device) and other (pump malposition, balloon herniation, hematoma, pain). Failure-free survival analysis was performed both for general and specific causes of revision. Predictors of mechanical and nonmechanical failures were determined by Cox proportional hazards model. A total of 1,020 patients met the inclusion criteria. After a median followup of 20 months, the estimated 5-year and 10-year overall revision-free survival was 60% and 40%, respectively. There were 214 AUS revisions: 59 (27.6%) for mechanical failures, 121 (56.5%) for nonmechanical failures and 34 (15.9%) other causes of revision. In multivariable Cox regression analysis, larger cuff size was the only predictor of overall revisions (HR=1.04 [1.01-1.07]; p=0.01) and revision for nonmechanical failure (HR=1.05 [1.02-1.09]; p=0.004). Half of the male AUS patients underwent device revision within the first 10 years after implantation. Nonmechanical failures are the primary cause of AUS revision in nonneurological men. Larger cuff size appears to be the main determinant of AUS revision risk.

Identifiants

pubmed: 34184925
doi: 10.1097/JU.0000000000001954
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1248-1257

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Auteurs

Imad Bentellis (I)

Department of Urology, University of Nice, Nice, France.

Mehdi El-Akri (M)

Department of Urology, University of Rennes, Rennes, France.

Jean-Nicolas Cornu (JN)

Department of Urology, University of Rouen, Rouen, France.

Thibaut Brierre (T)

Department of Urology, University of Toulouse, Toulouse, France.

Tiffany Cousin (T)

Department of Urology, University of Bordeaux, Bordeaux, France.

Victor Gaillard (V)

Department of Urology, University of Strasbourg, Strasbourg, France.

Hugo Dupuis (H)

Department of Urology, University of Rouen, Rouen, France.

Thibault Tricard (T)

Department of Urology, University of Strasbourg, Strasbourg, France.

Nicolas Hermieu (N)

Department of Urology, Bichat Hospital, Paris, France.

Priscilla Bertrand-Leon (P)

Department of Urology, University of Reims, Reims, France.

Daniel Chevallier (D)

Department of Urology, University of Nice, Nice, France.

Franck Bruyere (F)

Department of Urology, University of Tours, Tours, France.

Xavier Biardeau (X)

Department of Urology, University of Lille, Lille, France.

Jean-Francois Hermieu (JF)

Department of Urology, Bichat Hospital, Paris, France.

Pierre Lecoanet (P)

Department of Urology, University of Nancy, Nancy, France.

Grégoire Capon (G)

Department of Urology, University of Bordeaux, Bordeaux, France.

Xavier Game (X)

Department of Urology, University of Toulouse, Toulouse, France.

Christian Saussine (C)

Department of Urology, University of Strasbourg, Strasbourg, France.

Matthieu Durand (M)

INSERM U1081 - CNRS UMR 7284 Université Côte d'Azur, France.

Benoit Peyronnet (B)

Department of Urology, University of Rennes, Rennes, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH